Artios Pharma
Cambridge · Founded 2016 · $237.0M raised
- Headquarters
- Cambridge
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- artiospharma.com
- Total Funding
- $237.0M
- Last Round
- $153.0M Series CJan 2021
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Artios Pharma is a clinical-stage oncology company developing novel cancer therapies that exploit DNA Damage Response (DDR) and repair pathways leveraged by cancer cells to promote survival. Founded in 2016 and headquartered in Cambridge, UK, Artios has built a pipeline of first-in-class and best-in-class DDR inhibitors, including its lead program alnodesertib in Phase 2 trials for ATM-deficient pancreatic and colorectal cancers. The company raised $115 million in a Series D in November 2025 to advance its clinical programs.
Summary
Artios Pharma is a Biotech company based in Cambridge, founded in 2016. It has raised $237.0M in total across 2 rounds, most recently a $153.0M Series C round in Jan 2021. Investors include Omega Funds, TCGX and Andera Partners.
Funding History
Jan 2021
Sign up to see all 2 events
Funding: Series B through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/artios-pharma"><img src="https://indexed.vc/api/badge/company/artios-pharma" alt="Artios Pharma on Indexed.vc" width="260" height="76" /></a>